{"denoms":[{"counts":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"214"}],"units":"Participants"}],"groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"BG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"BG001","title":"Enfortumab Vedotin - Cohort 2"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"40","upperLimit":"84","value":"69.0"},{"groupId":"BG001","lowerLimit":"49","upperLimit":"90","value":"75.0"},{"groupId":"BG002","lowerLimit":"40","upperLimit":"90","value":"72.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"60"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"154"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"201"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"31"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"168"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"174"}]}],"title":"North America"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"14"}]}],"title":"Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"26"}]}],"title":"East Asia"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"77"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"126"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"11"}]}],"title":"2"}],"description":"ECOG performance status was used to assess participants disease progression, and ability to carry out daily living activities. 0=Normal activity; 1=Symptoms but ambulatory; 2=In bed \\<50% of the time; 3= In bed \\>50% of the time; 4=100% bedridden; 5=Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included all participants who received any amount of enfortumab vedotin."}